---
title: Sparsentan versus Irbesartan in Focal Segmental Glomerulosclerosis
date: '2023-11-03'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/37921461/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1LIK-026Y9bjRE4xDQ231BSa89BnY4O2Rfi-9WXQd8C31C6cqE&fc=20211015124055&ff=20231104180806&v=2.17.9.post6+86293ac
source: N Engl J Med
description: 'CONCLUSIONS: Among patients with FSGS, there were no significant between-group
  differences in eGFR slope at 108 weeks, despite a greater reduction in proteinuria
  with sparsentan than with irbesartan. (Funded by Travere Therapeutics; DUPLEX ClinicalTrials.gov
  number, ...'
disable_comments: true
---
CONCLUSIONS: Among patients with FSGS, there were no significant between-group differences in eGFR slope at 108 weeks, despite a greater reduction in proteinuria with sparsentan than with irbesartan. (Funded by Travere Therapeutics; DUPLEX ClinicalTrials.gov number, ...